{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:03:57Z","timestamp":1761091437425,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.vascn.2008.03.002","type":"journal-article","created":{"date-parts":[[2008,3,21]],"date-time":"2008-03-21T00:52:40Z","timestamp":1206060760000},"page":"212-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of different pharmacodynamic models for PK\u2013PD modeling of verapamil in renovascular hypertension"],"prefix":"10.1016","volume":"57","author":[{"given":"Facundo M.","family":"Bertera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier A.W.","family":"Opezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"H\u00f6cht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2008.03.002_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/bdd.402","article-title":"Pharmacodynamics of controlled release verapamil in patients with hypertension: An analysis using spline functions","volume":"25","author":"Aarons","year":"2004","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.vascn.2008.03.002_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling: History and perspectives","volume":"33","author":"Csajka","year":"2006","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1016\/j.vascn.2008.03.002_bib3","first-page":"349","article-title":"Animal models of hypertension and effect of drugs","volume":"35","author":"Badyal","year":"2003","journal-title":"Indian Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.vascn.2007.04.001","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: A microdialysis study","volume":"56","author":"Bertera","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"year":"1997","series-title":"ADAPT II User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D'Argenio","key":"10.1016\/j.vascn.2008.03.002_bib5"},{"key":"10.1016\/j.vascn.2008.03.002_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0163-7258(92)90044-Z","article-title":"Antihypertensive drugs: Individualized analysis and clinical relevance of kinetic\u2013dynamic relationships","volume":"53","author":"Donnelly","year":"1992","journal-title":"Pharmacology & Therapeutics"},{"issue":"Suppl 6","key":"10.1016\/j.vascn.2008.03.002_bib7","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/00005344-198812006-00027","article-title":"Factors determining the response to calcium antagonists in hypertension","volume":"12","author":"Donnelly","year":"1988","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-198611060-00002","article-title":"Clinical pharmacokinetics of verapamil, nifedipine and diltiazem","volume":"11","author":"Echizen","year":"1986","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.vascn.2008.03.002_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00568400","article-title":"Simultaneous determination of the intravenous and oral pharmacokinetic parameters of d,l-verapamil using stable isotope-labelled verapamil","volume":"19","author":"Eichelbaum","year":"1981","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0022-3565(24)35087-6","article-title":"Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats","volume":"291","author":"Elliot","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"year":"1982","series-title":"Pharmacokinetics","author":"Gibaldi","key":"10.1016\/j.vascn.2008.03.002_bib11"},{"key":"10.1016\/j.vascn.2008.03.002_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/bdd.289","article-title":"Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina","volume":"23","author":"Gupta","year":"2002","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.vascn.2008.03.002_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2165\/00003088-198409010-00002","article-title":"Clinical pharmacokinetics of verapamil","volume":"9","author":"Hamann","year":"1984","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.vascn.2008.03.002_bib14","first-page":"469","article-title":"Concentration\/effect analysis of verapamil: Evaluation of different approaches","volume":"31","author":"Harder","year":"1993","journal-title":"International Journal of Clinical Pharmacology, Therapy and Toxicology"},{"key":"10.1016\/j.vascn.2008.03.002_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00045391-199408000-00003","article-title":"Concentration\/effect analysis of antihypertensive drugs","volume":"1","author":"Harder","year":"1994","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.vascn.2008.03.002_bib16","first-page":"665","article-title":"Concentration\/effect relationship and enantioselective analysis of verapamil in hypertensive patients","volume":"19","author":"Harder","year":"1992","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.vascn.2005.01.002","article-title":"Application of the microdialysis technique for the pharmacokinetic-pharmacodynamic (PK-PD) modeling of beta-blockers","volume":"52","author":"H\u00f6cht","year":"2005","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2008.03.002_bib17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0731-7085(02)00652-0","article-title":"Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters","volume":"31","author":"H\u00f6cht","year":"2003","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.vascn.2008.03.002_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1570163043334848","article-title":"Microdialysis in drug discovery","volume":"1","author":"H\u00f6cht","year":"2004","journal-title":"Current Drug Discovery Technologies"},{"key":"10.1016\/j.vascn.2008.03.002_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vascn.2006.02.007","article-title":"Applicability of reverse microdialysis in pharmacological and toxicological studies","volume":"55","author":"H\u00f6cht","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2008.03.002_bib20","series-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","first-page":"845","article-title":"Therapy of hypertension","author":"Hoffman","year":"2006"},{"key":"10.1016\/j.vascn.2008.03.002_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/clpt.1981.4","article-title":"Verapamil protein binding in patients and in normal subjects","volume":"29","author":"Keefe","year":"1981","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2008.03.002_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000139276","article-title":"The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo","volume":"50","author":"Loch","year":"1995","journal-title":"Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/bdd.2510140702","article-title":"Intravenous verapamil kinetics in rats: Marked arteriovenous concentration difference and comparison with humans","volume":"14","author":"Manitpisitkul","year":"1993","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.vascn.2008.03.002_bib24","doi-asserted-by":"crossref","first-page":"16D","DOI":"10.1016\/0002-9149(86)90800-3","article-title":"Kinetics and dynamics of calcium entry antagonists in systemic hypertension","volume":"57","author":"McAllister","year":"1986","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.vascn.2008.03.002_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0940-2993(99)80027-X","article-title":"Influence of rethane and ketamine on rat hepatic cytochrome P450 in vivo","volume":"51","author":"Meneguz","year":"1999","journal-title":"Experimental and Toxicological Pathology"},{"issue":"suppl 5","key":"10.1016\/j.vascn.2008.03.002_bib26","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00004872-199715055-00005","article-title":"Clinical relevance of optimal pharmacokinetics in the treatment of hypertension","volume":"15","author":"Meredith","year":"1997","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.vascn.2008.03.002_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2125.1985.tb05038.x","article-title":"Verapamil pharmacokinetics and apparent hepatic and renal blood flow","volume":"20","author":"Meredith","year":"1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1248\/bpb.24.806","article-title":"Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits","volume":"24","author":"Mori","year":"2001","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.vascn.2008.03.002_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10517-006-0204-2","article-title":"Reversibility of changes in hepatic vessels after correction of experimental aortic coarctation","volume":"141","author":"Novikov","year":"2006","journal-title":"Bulletin of Experimental Biology and Medicine"},{"key":"10.1016\/j.vascn.2008.03.002_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0188-4409(00)00242-3","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling: Why?","volume":"31","author":"P\u00e9rez-Urizar","year":"2000","journal-title":"Archives of Medical Research"},{"key":"10.1016\/j.vascn.2008.03.002_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0002-9343(86)90788-6","article-title":"Calcium metabolism, renin activity, and the antihypertensive effects of calcium channel blockade","volume":"15","author":"Resnick","year":"1986","journal-title":"The American Journal of Medicine"},{"issue":"6 Pt 2","key":"10.1016\/j.vascn.2008.03.002_bib32","doi-asserted-by":"crossref","first-page":"179S","DOI":"10.1093\/ajh\/2.6.179S","article-title":"Calcium metabolism in the pathophysiology and treatment of clinical hypertension","volume":"2","author":"Resnick","year":"1989","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.vascn.2008.03.002_bib33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-199345060-00003","article-title":"Drug therapy of renovascular hypertension","volume":"45","author":"Rosenthal","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.vascn.2008.03.002_bib34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1139\/y68-137","article-title":"A method for production of experimental hypertension in rats","volume":"46","author":"Rojo-Ortega","year":"1968","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib35","first-page":"H812","article-title":"Losartan improves baroreflex control of heart rate of coarcted hypertensive rats","volume":"269","author":"Santos","year":"1995","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.vascn.2008.03.002_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1023\/A:1023277201179","article-title":"Estimating potency for the Emax-model without attaining maximal effects","volume":"26","author":"Schoemaker","year":"1998","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.vascn.2008.03.002_bib37","first-page":"61","article-title":"Morphological changes of hepatic vessels in experimental aortal coarctation and after its elimination","volume":"124","author":"Shormanov","year":"2003","journal-title":"Morfologiia"},{"key":"10.1016\/j.vascn.2008.03.002_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02333025","article-title":"Pharmacokinetic estimations from microdialysis data","volume":"43","author":"St\u00e5hle","year":"1992","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2008.03.002_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3181\/00379727-203-43578","article-title":"Contractile responses to Bay K 8644 in rats with coarctation-induced hypertension","volume":"203","author":"Storm","year":"1993","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.vascn.2008.03.002_bib40","first-page":"1","article-title":"Pharmacokinetic\/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine","volume":"4","author":"Toutain","year":"2002","journal-title":"AAPS Pharmaceutical Sciences"},{"key":"10.1016\/j.vascn.2008.03.002_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.1981.126","article-title":"Direct determination of hepatic extraction of verapamil in cardiac patients","volume":"30","author":"Woodcock","year":"1981","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2008.03.002_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3181\/00379727-189-42799","article-title":"Direct correlation between calcium content and blood pressure: A study of aortic coarctation in rats","volume":"189","author":"Yang","year":"1988","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.vascn.2008.03.002_bib43","first-page":"366","article-title":"Calcium chelation and calcium-channel blockade in anesthetized acute renovascular hypertensive dogs","volume":"10","author":"Zawada","year":"1984","journal-title":"Mineral and Electrolyte Metabolism"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871908000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871908000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T23:53:14Z","timestamp":1761004394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871908000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S1056871908000233"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2008.03.002","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of different pharmacodynamic models for PK\u2013PD modeling of verapamil in renovascular hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2008.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}